comparemela.com

Neonatal Morbidity News Today : Breaking News, Live Updates & Top Stories | Vimarsana

LDI:REACH project leads on knowledge-sharing to improve effective coverage of maternal health interventions

FIGO member society congresses and conferences serve as a powerful platform for sharing knowledge, fostering collaboration and driving innovation  –  all crucial aspects of FIGO’s LDI:REACH programme. 

Discontinuing oxytocin during active labour has no significant impact on neonatal morbidity

1. Neonatal morbidity rate was comparable between the continuous oxytocin and discontinuous oxytocin groups. 2. There was no significant difference in adverse events between both groups. Evidence Rating Level: 1 (Excellent) Study Rundown: Oxytocin is known for reducing labour duration but may pose risks for neonatal morbidity. In the multicenter STOPOXY trial, participants receiving oxytocin

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.